Compass Therapeutics (CMPX) Common Equity: 2023-2025
Historic Common Equity for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $209.6 million.
- Compass Therapeutics' Common Equity rose 51.46% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 51.46%. This contributed to the annual value of $125.2 million for FY2024, which is 15.69% down from last year.
- As of Q3 2025, Compass Therapeutics' Common Equity stood at $209.6 million, which was up 124.89% from $93.2 million recorded in Q2 2025.
- Over the past 5 years, Compass Therapeutics' Common Equity peaked at $209.6 million during Q3 2025, and registered a low of $93.2 million during Q2 2025.
- For the 3-year period, Compass Therapeutics' Common Equity averaged around $148.4 million, with its median value being $148.5 million (2023).
- Over the last 5 years, Compass Therapeutics' Common Equity had its largest YoY gain of 51.46% in 2025, and its largest YoY loss of 36.21% in 2025.
- Quarterly analysis of 3 years shows Compass Therapeutics' Common Equity stood at $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then skyrocketed by 51.46% to $209.6 million in 2025.
- Its last three reported values are $209.6 million in Q3 2025, $93.2 million for Q2 2025, and $110.3 million during Q1 2025.